Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension

NCT03422653 is registered in ClinicalTrials.gov with Cara Therapeutics, Inc. as lead sponsor.

NCT NCT03422653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension
Lead sponsor
Cara Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 20, 2018
Completion date
March 26, 2020
Enrollment
378 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

uremic pruritus